Renalytix Plc (NASDAQ:RNLX) Q2 2023 Earnings Conference Call March 30, 2023 8:30 AM ET
Company Participants
Peter DeNardo - CapComm Partners
James McCullough - CEO
O. James Sterling - CFO
Thomas McLain - President
Fergus Fleming - CTO
Conference Call Participants
Daniel Arias - Stifel
Unidentified Analyst - BTIG
Jens Lindqvist - Investec
Randy Baron - Pinnacle Associates
Chaitanya Gollakota - H.C. Wainwright
Operator
Good morning and welcome to the Renalytix Conference Call to review Second Quarter and First Half Fiscal Year 2023 Financial Results. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter DeNardo of CapComm Partners for a few introductory comments.
Peter DeNardo
Thank you, Michelle. Good morning and welcome to the Renalytix conference call to review second quarter and first half fiscal year 2023 financial results. At this time all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder this call is being recorded for replay purposes. Thank you all for participating in today’s call. Joining me today from Renalytix to provide formal remarks are James McCullough, Chief Executive Officer; Thomas McLain, President; and James Sterling, Chief Financial Officer. In addition, Fergus Fleming, Chief Technology Officer will be on hand to join us for the question-and-answer session.
Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. Examples of these statements include without limitation, the potential benefits, including economic savings of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects for KidneyIntelX including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail cost of chronic and end stage kidney disease, optimize care delivery, and improve patient outcomes, trends in our market and potential benefits of government policy change, the impact of COVID-19 and other world events on our business, our expectations for hiring, product development, strategic partnerships and collaborations, reimbursement decisions, clinical studies and regulatory submissions, our business strategies and future growth including plans, expectations, and opportunities for financing our operations, and revenue projections and guidance. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.